非横纹肌肉瘤软组织肉瘤术前放化疗联合或不联合帕唑帕尼的结局:儿童肿瘤学组与NRG肿瘤学报告
ARST1321是一项II期研究,比较中高危、化疗敏感的身体壁或四肢非横纹肌肉瘤软组织肉瘤患者接受术前放化疗联合或不联合帕唑帕尼的疗效。预设期中分析发现联合帕唑帕尼组接近完全病理缓解率显著更高后提前终止入组。
要点
- 联合帕唑帕尼组接近完全病理缓解率显著更高,但生存结局无统计学显著差异。
- 3年无事件生存:A组52.5% vs B组50.6%,P=0.8677。
- 3年总生存:A组75.7% vs B组65.4%,P=0.1919。
核心结论
- 虽然加用帕唑帕尼后接近完全病理缓解率显著更高,但两方案结局无统计学显著差异。
研究设计与样本
- ARST1321为II期研究,纳入儿童和成人中高危、化疗敏感的身体壁或四肢非横纹肌肉瘤软组织肉瘤患者。
- 预设期中分析发现加用帕唑帕尼组接近完全病理缓解率显著更高后,入组提前终止。
主要发现
- 截至2021年12月31日,中位生存随访3.3年(范围0.1-5.8年)。
- 意向治疗分析中,3年无事件生存方案A为52.5%(95%CI 34.8-70.2),方案B为50.6%(95%CI 32-69.2),P=0.8677(log-rank检验)。
- 3年总生存方案A为75.7%(95%CI 59.7-91.7),方案B为65.4%(95%CI 48.1-82.7),P=0.1919(log-rank检验)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 入组在预设期中分析显示加用帕唑帕尼组接近完全病理缓解率显著更高后提前终止。
- 随访时间有限,中位生存随访3.3年(范围0.1-5.8年)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.ARST1321 was a phase II study designed to compare the near complete pathologic response rate after preoperative chemoradiation with/without pazopanib in children and adults with intermediate-/high-risk chemotherapy-sensitive body wall/extremity non-Rhabdomyosarcoma Soft Tissue Sarcoma (ClinicalTrials.gov identifier: NCT02180867). Enrollment was stopped early following a predetermined interim analysis that found the rate of near complete pathologic response to be significantly greater with the addition of pazopanib. As a planned secondary aim of the study, the outcome data for this cohort were analyzed. Eight-five eligible patients were randomly assigned to receive (regimen A) or not receive (regimen B) pazopanib in combination with ifosfamide and doxorubicin + preoperative radiotherapy followed by primary resection at week 13 and then further chemotherapy at week 25. As of December 31, 2021, at a median survivor follow-up of 3.3 years (range, 0.1-5.8 years), the 3-year event-free survival for all patients in the intent-to-treat analysis was 52.5% (95% CI, 34.8 to 70.2) for regimen A and 50.6% (95% CI, 32 to 69.2) for regimen B (P = .8677, log-rank test); the 3-year overall survival was 75.7% (95% CI, 59.7 to 91.7) for regimen A and 65.4% (95% CI, 48.1 to 82.7) for regimen B (P = .1919, log-rank test). Although the rate of near complete pathologic response was significantly greater with the addition of pazopanib, outcomes were not statistically significantly different between the two regimens.
引用
- Weiss AR, Chen YL, Scharschmidt TJ, et al. Outcomes After Preoperative Chemoradiation With or Without Pazopanib in Non-Rhabdomyosarcoma Soft Tissue Sarcoma: A Report From Children's Oncology Group and NRG Oncology. J Clin Oncol. 2023. PMID: 37523624. doi:10.1200/JCO.23.00045
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。